Diabetes mellitus, a chronic metabolic disorder defined by persistent hyperglycemia, affects over 500 million people worldwide and remains a leading cause of morbidity and mortality. While the disease is primarily characterized by defects in insulin secretion or action, it is increasingly recognized that a state of chronic, low‑grade inflammation underpins many of its complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy. This inflammatory milieu is not merely a consequence of metabolic derangement; it actively contributes to insulin resistance and beta‑cell dysfunction. Over the past two decades, research has shed light on the role of the innate immune system in this process, with particular attention to the complement system—a network of serum proteins that orchestrate immune surveillance and inflammation. Complement components, especially C3 and C4, have emerged as key players in the inflammatory cascade associated with diabetes. Understanding how these proteins interact with metabolic pathways offers potential avenues for improved diagnostics and targeted therapies. This article explores the relationship between serum complement components and diabetes‑related inflammation, summarizing current evidence and discussing clinical implications.

The Complement System: An Overview

The complement system is a highly conserved part of the innate immune response, comprising more than 30 soluble and membrane‑bound proteins. These proteins are synthesized primarily in the liver and circulate in an inactive form until triggered by pathogens, damaged cells, or other danger signals. Upon activation, the complement cascade proceeds through three major pathways: classical, lectin, and alternative. All three converge at the cleavage of central component C3, leading to the generation of effector molecules that promote opsonization, lysis of target cells, and inflammation.

Key components include C1q, C2, C4, C3, C5, and the membrane attack complex (MAC) proteins. The classical pathway is initiated by antibody‑antigen complexes or by C1q binding directly to pathogen surfaces. The lectin pathway is triggered by mannose‑binding lectin recognizing carbohydrate patterns. The alternative pathway is constitutively active at a low level and provides amplification. Activation of C3 generates C3a and C3b; C3b opsonizes targets, while C3a acts as an anaphylatoxin, recruiting and activating immune cells. Further downstream, C5 cleavage yields C5a, a potent pro‑inflammatory molecule, and C5b, which initiates MAC formation. Regulation is critical to prevent self‑damage; multiple regulatory proteins such as factor H, factor I, and CD55 inhibit excessive activation. Dysregulation of these components is implicated in autoimmune diseases, age‑related macular degeneration, and, increasingly, metabolic disorders.

In the context of diabetes, the complement system is not merely a bystander. Adipose tissue, which is expanded and dysfunctional in obesity‑driven type 2 diabetes, releases a variety of complement proteins and regulatory factors. Furthermore, hyperglycemia can directly alter complement protein expression and activity through mechanisms involving advanced glycation end products and oxidative stress. The interplay between complement activation and the inflammatory state of metabolic tissues is complex and continues to be an active area of investigation.

Diabetes and Chronic Inflammation

Type 2 diabetes (T2D) is characterized by insulin resistance and progressive beta‑cell failure, conditions tightly linked to chronic inflammation. Adipose tissue from obese individuals shows increased infiltration of macrophages and other immune cells, creating a pro‑inflammatory environment. Cytokines such as tumor necrosis factor‑alpha (TNF‑α), interleukin‑6 (IL‑6), and monocyte chemoattractant protein‑1 (MCP‑1) are elevated in the circulation and within adipose tissue. This inflammatory state impairs insulin signaling through serine phosphorylation of insulin receptor substrate proteins, contributing to systemic insulin resistance. Additionally, inflammatory mediators can directly damage pancreatic beta cells, reducing insulin secretion capacity.

The complement system participates in this inflammatory milieu in several ways. Complement activation products, particularly C3a and C5a, promote chemotaxis and activation of immune cells, leading to enhanced cytokine release. Complement also interacts with lipid metabolism: C3adesArg, also known as acylation stimulating protein (ASP), stimulates triglyceride synthesis and storage in adipocytes, linking complement to lipid accumulation and obesity. Elevated concentrations of complement components in the circulation may reflect both increased hepatic production in response to inflammatory signals and local production by adipose tissue. As a result, serum levels of C3 and C4 have been proposed as biomarkers of low‑grade inflammation in metabolic disease, potentially providing information beyond traditional inflammatory markers like C‑reactive protein (CRP).

Clinical Evidence Linking Complement Components to Diabetes

Numerous epidemiological studies have reported that individuals with type 2 diabetes have higher serum levels of C3 and C4 compared to normoglycemic controls. A meta‑analysis of 24 studies found that C3 levels were significantly elevated in patients with T2D, with a standardized mean difference of 0.71. Elevated C3 has also been associated with increased risk of developing diabetes in prospective cohorts. For instance, the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam study showed that higher baseline C3 concentrations predicted incident type 2 diabetes over a 7‑year follow‑up, independent of age, sex, BMI, and waist circumference. Similarly, C4 levels have been linked to diabetes prevalence and to markers of insulin resistance, though the associations are sometimes weaker or more variable than those for C3.

Complement components also correlate with diabetic complications. In patients with established diabetes, elevated C3 and C4 have been associated with albuminuria, a marker of diabetic nephropathy, and with increased carotid intima‑media thickness, a surrogate for atherosclerosis. A study of 1,289 patients with type 2 diabetes found that those in the highest quartile of serum C3 had a 1.8‑fold higher risk of cardiovascular events over a 5‑year period compared to those in the lowest quartile, after adjusting for traditional risk factors. These findings suggest that complement levels may not only reflect inflammation but also actively contribute to vascular damage.

C3 and Its Metabolic Implications

C3 is the most abundant complement protein and sits at the intersection of immune defense and metabolic regulation. Its cleavage generates C3a, which is rapidly converted to C3adesArg (ASP) by carboxypeptidase N. ASP is a hormone‑like molecule that acts on adipocytes through the C5L2 receptor to enhance glucose uptake, fatty acid esterification, and triglyceride storage. In obesity, both C3 and ASP levels are elevated, and this may represent a compensatory mechanism to accommodate excess energy intake. However, chronic overactivation of this pathway may contribute to adipose tissue dysfunction, inflammation, and insulin resistance.

Beyond ASP, other C3 fragments have direct pro‑inflammatory effects. C3a stimulates chemotaxis of neutrophils and monocytes and promotes release of histamine from mast cells and basophils. C3b, the larger fragment, opsonizes cells and targets them for phagocytosis. In the context of diabetes, increased production of C3 by the liver and adipose tissue leads to a state of sustained complement activation. This is evidenced by elevated levels of C3a and soluble C5b‑9 (the MAC) in the circulation of patients with T2D. The resulting inflammation can further impair insulin signaling and exacerbate metabolic dysfunction. Moreover, C3 has been shown to interact with the renin‑angiotensin system, another pathway implicated in diabetic complications, suggesting a potential amplifying loop.

Recent research has also identified genetic variations in the C3 gene that may influence diabetes risk. Polymorphisms affecting C3 expression or function could modulate complement activity and the inflammatory response. For example, a common variant in the C3 gene (rs2230199, leading to an Arg102Gly substitution) has been associated with higher C3 levels and increased risk of age‑related macular degeneration, but its role in diabetes is less clear. Future studies using Mendelian randomization may help establish causal relationships between C3 and diabetes‑related inflammation.

C4 and Vascular Complications

C4 is a component of the classical and lectin pathways. Like C3, it is synthesized mainly in the liver, but also by macrophages and other cell types. Two major isoforms exist: C4A and C4B, with differences in binding specificity. In the circulation, C4 is present as an inactive precursor. Upon activation by C1s, it is cleaved into C4a and C4b; C4b then binds to the target surface and participates in the formation of the C3 convertase (C4b2a). Elevated serum C4 levels have been reported in type 2 diabetes, although the association is often weaker than for C3.

The role of C4 in diabetic complications, particularly nephropathy and retinopathy, has garnered attention. In a cross‑sectional study of patients with type 2 diabetes, those with microalbuminuria or overt proteinuria had significantly higher C4 levels compared to those with normal albumin excretion. A follow‑up study over 3 years found that baseline C4 was an independent predictor of progression to macroalbuminuria. The mechanism may involve C4 deposition in the glomerular basement membrane, contributing to immune‑complex formation and complement‑mediated injury. Additionally, C4 activation can generate C4a, an anaphylatoxin that promotes vasodilation and increased permeability, potentially exacerbating vascular leak in the retina and glomeruli.

In diabetic retinopathy, complement activation has been implicated in the pathogenesis of microvascular damage. Levels of C4d, a degradation product indicating C4 activation, have been found elevated in vitreous humor of patients with proliferative diabetic retinopathy. These findings support a role for the classical/lectin pathway in the inflammatory component of diabetic eye disease. While specific C4‑targeted therapies are not yet available, these observations suggest that monitoring C4 levels may help identify patients at higher risk for vascular complications.

Complement as a Biomarker and Therapeutic Target

The consistent associations between complement components and diabetes‑related inflammation make them attractive candidates for clinical use. Measurement of serum C3 and C4 is relatively inexpensive and widely available in clinical laboratories. Incorporating these markers into risk stratification algorithms could improve identification of individuals with heightened inflammatory burden who may benefit from more intensive metabolic control or anti‑inflammatory interventions. For example, a C3‑based risk score might help predict incident diabetes in high‑risk populations, or identify patients with established diabetes who are at elevated risk for cardiovascular events and nephropathy.

However, challenges remain. Complement levels are influenced by acute‑phase responses, infections, and autoimmune diseases, which can confound interpretation. Moreover, reference ranges vary by age, sex, and ethnicity. Standardization of assays and careful clinical context are needed before widespread implementation. Despite these limitations, several studies have demonstrated that adding C3 to traditional risk models improves discrimination for cardiovascular outcomes in diabetes. A prospective study of 1,876 patients with type 2 diabetes found that the addition of C3 to a model containing age, sex, HbA1c, blood pressure, lipids, and smoking raised the area under the receiver‑operating characteristic curve for cardiovascular events from 0.71 to 0.74 (p<0.01).

On the therapeutic front, complement inhibition is an emerging strategy in inflammatory diseases. Eculizumab, a monoclonal antibody that blocks C5 cleavage, is approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its use in diabetic complications is exploratory but has shown promise in preclinical models. In a mouse model of diabetic nephropathy, eculizumab reduced albuminuria, glomerular complement deposition, and inflammatory cytokine expression. Small molecule inhibitors targeting C3 or the alternative pathway are also in development, such as compstatin analogues, which have shown efficacy in age‑related macular degeneration and could potentially be repurposed for metabolic disease.

Other approaches include modulating complement regulators. Recombinant factor H-like proteins or gene therapies to increase factor H expression might limit aberrant complement activation in the kidney and retina. Additionally, lifestyle interventions that reduce obesity and improve metabolic health have been shown to lower C3 levels. Weight loss through bariatric surgery or dietary modification can lead to significant reductions in serum C3 and improvements in inflammatory markers. This suggests that complement levels are responsive to metabolic status and may serve as a surrogate endpoint in clinical trials of anti‑inflammatory or weight‑loss strategies.

Despite the promise, translating complement‑based biomarkers and therapies into routine diabetes care will require larger clinical trials and a deeper understanding of the mechanisms involved. The complement system is complex, with context‑dependent beneficial and detrimental effects. Targeting it systemically could increase susceptibility to infections, given its role in immune defense. Therefore, future strategies may need to be tissue‑specific or pathway‑selective to minimize risks.

Conclusion

The relationship between serum complement components and diabetes‑related inflammation is both intricate and clinically relevant. Evidence consistently demonstrates that elevated C3 and C4 levels are associated with type 2 diabetes, insulin resistance, obesity, and diabetic complications. These complement proteins do not merely reflect systemic inflammation; they actively participate in metabolic pathways, from lipid metabolism to endothelial damage. As such, they present dual opportunities: as biomarkers for risk stratification and as targets for therapeutic intervention. While challenges remain—particularly in terms of assay standardization and the risk of immunosuppression—the growing body of research suggests that the complement system deserves a place alongside more traditional inflammatory markers in the study and management of diabetes. Continued investigation into the precise molecular mechanisms, along with well‑designed clinical trials of complement inhibitors, will clarify whether modulating complement can improve outcomes for the millions of individuals affected by this relentless disease. For those seeking further reading, reviews in PubMed and Diabetes provide comprehensive overviews, while a detailed meta‑analysis on C3 in T2D is available here. The path from bench to bedside is long, but the complement system’s role in diabetes‑related inflammation is no longer a fringe hypothesis—it is a central piece of the puzzle.